INSM
NASDAQ
US
Insmed Incorporated - Common Stock
$162,43
▼ $-2,43
(-1,47%)
Vol. 1.8M
6
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$37.1B
ROE
-183,5%
Margine
-264,8%
D/E
77,03
Beta
1,10
52W
$60–$213
Consenso Wall Street
26 analisti · Apr 20269
Acquisto forte
16
Compra
1
Mantieni
0
Vendi
0
Vendita forte
96,2%
Rating Compra
Grafico dei Prezzi
Titoli simili
GILD
Gilead Sciences Inc
P/E 18,8
$152.3B
VRTX
Vertex Pharmaceuticals Inc
P/E 31,3
$115.0B
REGN
Regeneron Pharmaceuticals Inc
P/E 17,7
$81.1B
ALNY
Alnylam Pharmaceuticals Inc
P/E 1205,9
$52.5B
NTRA
Natera Inc
$31.7B
BIIB
Biogen Inc
P/E 16,0
$25.8B
UTHR
United Therapeutics Corp
P/E 16,5
$21.0B
RVMD
Revolution Medicines Inc
$15.4B
MRNA
Moderna Inc
$11.5B
Utili
Tasso di battuta: 0,0%
Prossimo report
Mag 06, 2026
Stima EPS: $-1,02
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-1,02 | — | — |
| Dic 2025 | $-1,32 | $-1,54 | $-0,22 |
| Set 2025 | $-1,37 | $-1,75 | $-0,38 |
| Giu 2025 | $-1,32 | $-1,70 | $-0,38 |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -195.4% | -195.4% | -195.4% | -183.5% | -183.5% | -183.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -299.5% | -259.8% | -259.8% | -264.8% | -264.8% | -264.8% |
| Gross Margin | 73.9% | 75.7% | 75.7% | 76.5% | 76.5% | 76.5% |
| D/E Ratio | 58.22 | 45.14 | 45.14 | 59.71 | 77.03 | 77.03 |
| Current Ratio | 6.68 | 6.68 | 6.68 | 4.63 | 4.63 | 4.63 |
Rapporti chiave
ROA (TTM)
-54,6%
P/S (TTM)
83,03
P/B
43,3
EPS (TTM)
$-6,18
CF/Share
$-5,17
Crescita ricavi 3A
+24,5%
52W High
$212,75
52W Low
$60,40
$60,40
Intervallo 52 settimane
$212,75
Як INSM виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка INSM vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
83,0
▲
546%
sopra
peer
(12,9)
vs Peer
vs Settore
Più costoso
P/B
43,3
▲
1659%
sopra
peer
(2,5)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість INSM vs аналоги Biotechnology
ROE
-183,6%
▼
173%
sotto
peer
(-67,3%)
vs Peer
vs Settore
Debole
Net margin
-264,8%
▲
8%
sopra
peer
(-286,8%)
vs Peer
vs Settore
Debole
Валова маржа
76,5%
▼
3%
sotto
peer
(78,6%)
vs Peer
vs Settore
Debole
ROA
-54,6%
▼
17%
sotto
peer
(-46,7%)
vs Peer
vs Settore
Sotto media
Фінансове здоровʼя INSM vs аналоги Biotechnology
D/E ratio
77,0
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
4,6
▲
4%
sopra
peer
(4,4)
vs Peer
vs Settore
In linea
Beta
1,1
▲
14%
sopra
peer
(1,0)
vs Peer
vs Settore
Meno volatile
Радар фундаменталів INSM
INSM
Mediana peer
Industria
INSM прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio